Lymphatic targeting of anti-HIV nucleosides: Distribution of 2',3'-dideoxyinosine after intravenous and oral administration of dipalmitoylphosphatidyl prodrug in mice

Antiviral Research

Volumn 34, Issue 3, 1997, Pages 91-99

  Manouilov, Konstantine K ^a   Xu, Zu Sheng ^a   Boudinot, F Douglas ^a   Schinazi, Raymond F ^b   Chu, Chung K ^a  

^a UNIVERSITY OF GEORGIA   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

2',3' dideoxyinosine; Anti HIV nucleosides; Lymphatic targeting

Indexed keywords

ANTIVIRUS AGENT; DIDANOSINE; NUCLEOSIDE ANALOG; PRODRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; BIOAVAILABILITY; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG LYMPH LEVEL; DRUG SYNTHESIS; DRUG TARGETING; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VITRO STUDY; INTRAVENOUS DRUG ADMINISTRATION; MASS SPECTROMETRY; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

ADMINISTRATION, ORAL; ANIMALS; ANTI-HIV AGENTS; DIDANOSINE; FEMALE; INJECTIONS, INTRAVENOUS; LYMPHATIC SYSTEM; MICE; PRODRUGS; TISSUE DISTRIBUTION;

EID: 0030994635     PISSN: 01663542     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0166-3542(96)01023-6     Document Type: Article

References (14)

1. Beach, J.W., Kim, H.O., Jeong, L.S., Nampalli, S., Islam, Q., Ahn, S.K., Babu, J.R. and Chu, C.K. (1992) A highly stereoselective synthesis of anti-HIV 2′,3′-dideoxy- and 2′,3′-didehydro-2′,3′-dideoxynucleosides. J. Org. Chem. 57, 3887-3894.
2. Chu, C.K., Ma, T.W., Shanmuganathan, K., Wang, C.G., Xiang, Y.J., Pai, S.B., Yao, G.Q., Sommadossi, J.-P., and Cheng, Y.-C. (1995) 2′-Fluoro-5-methyl-β-L-arabinofuranosyl (L-FMAU) as a novel antiviral agent for hepatitis B and Epstein-Barr virus. Antimicrob. Agents Chemother. 39, 979-981.
3. Embretson, J.M., Zupancic, Ribas, J.L., Burke, A., Racz, P., Tenner-Racz, K., and Haase, A.T. (1993) Massive covert infection of helper T-lymphocytes and macrophages by HIV during the incubation period of AIDS. Nature 362, 359-364.
4. Hostetler, K., Stuhmiller, L.M., Lenting, H.B.M., van den Bosch, H. and Richman, D.D.(1990) Synthesis and antiretroviral activity of phospholipid analogs of azidothymidine and other antiviral nucleosides. J. Biol. Chem. 265, 6112-6117.
5. Hostetler, K.Y., Richman, D.D., Sridhar, C.N., Felgner, P.L., Felgner, J., Ricci, J., Gardner, M.F., Selleseth, D.W. and Ellis, M.N. (1994) Phosphatidyl-azidothymidine and phosphatidyl-ddC: assessment of uptake in mouse lymphoid tissues and antiviral activities in human immunodeficiency virus-infected cells and in Rauscher leukemia virus-infected mice. Antimicrob. Agents Chemother. 38, 2792-2797.
6. Manouilov, K.K., Fedorov, I.I., White, C.A., Boudinot, F.D., Kotra, L.P, Schinazi, R.F., Hong, C.I. and Chu, C.K. (1995) Targeting for the lymphatic system by an anti-HIV nucleoside prodrug dipalmitoylphosphatidyl-AZDU (DPP-AZDU) and dipalmitoylphosphatidyl-AZT (DPP-AZT). Antiviral Chem. Chemother. 6, 230-238.
7. Morse, G.D., Shelton, M.J. and O'Donnell, A.M. (1993) Comparative pharmacokinetics of antiviral nucleoside analogues. Clin. Pharmacol. 24, 101-123.
8. Murphy, R. (1995) Clinical aspects of human immunodeficiency virus disease: clinical rationale for treatment. J. Infect. Dis. 171 (Suppl. 2), S81-S87.
9. Pantaleo, G., Graziosi, C., Demarest, J.F., Butini, L., Montroni, M., Fox, C.H., Orenstein, K.M., Kotler, D.P. and Fauci, F.A. (1993) HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease. Nature 362, 355-358.
10. Rocci, M.L. and Jusko, W.J. (1983) LAGRAN program for area and moments in pharmacokinetic analysis. Comp. Prog. Biomed. 16, 203-216.
11. Russell, J.W. and Klunk, L.J. (1989) Comparative pharmacokinetics of new anti-HIV agents: 2′,3′-dideoxyadenosine and 2′,3′- dideoxyinosine. Biochem. Pharmacol. 38, 1385-1388.
12. Tartaglione, T.A., Fletcher, C.V. and Collier, A.C. (1993) Principles and management of acquired immunodeficiency syndrome. In: Pharmacotherapy. A pathophysiologic Approach (DiPiro, J.T., Talbert, R.L., Hayes, P.E., Yee, G.C., Matzke G.R. and Posey, L.M., eds), pp. 1837-1867, Appleton and Lange, Norwalk, CT.
13. Xie, H., Voronkov, M., Liotta, D.C., Korba, B.A., Schinazi, R.F., Richman, D.D. and Hostetler, K.Y. (1995) Phosphatidyl- 2′,3′-dideoxy-3′-thiacytidine: synthesis and antiviral activity in hepatitis B- and HIV-1-infected cells. Antiviral Res. 228, 113-120.
14. Yuan, J. (1993) Estimation of variance for AUC in animal studies. J. Pharm. Sci. 82, 761-763.